rethinkTHC Search
Menu
Study breakdown

THC and CBD Suppressed a Key Inflammatory Signal in Human Immune Cells

LaboratoryPreliminary evidence
The takeaway

THC and CBD blocked the production of IL-1beta by human CD16+ monocytes activated through viral sensing pathways, working by inhibiting inflammasome assembly and caspase-1 activity rather than changing gene expression.

Immunology researchers, rheumatologists, and those interested in the molecular mechanisms of cannabinoid anti-inflammatory effects.

What the researchers found

THC and CBD suppressed IL-1beta production by blocking inflammasome formation and caspase-1 activity in TLR7/TLR8-activated CD16+ monocytes. This occurred at the post-translational level; mRNA expression of IL1B, CASP1, NLRP3, and PYCARD was unaffected. A CB2-selective agonist (JWH-015) did not replicate these effects, indicating the mechanism is not mediated by CB2 receptors alone.

Why it matters

IL-1beta is a master inflammatory cytokine implicated in conditions from rheumatoid arthritis to HIV-associated neurological disease. Understanding exactly how cannabinoids suppress it at the protein level (not gene level) provides a specific mechanistic target for therapeutic development.

The numbers in context

THC Kd values not reported in this study. THC was more efficacious than CBD. JWH-015 (CB2 agonist) had no effect. mRNA for IL1B, CASP1, NLRP3, PYCARD unaffected by THC. Minimal THC effects on TLR8-mediated AIM2 expression.

How the study worked

Primary human CD16+ and CD16- monocytes were isolated and pretreated with THC, CBD, or JWH-015, then activated through TLR7 or TLR8 (viral sensing receptors). Inflammasome formation, caspase-1 activity, cytokine secretion, and gene expression were measured.

What this study cannot tell us

In vitro study using isolated human monocytes outside their tissue context. Concentrations of THC and CBD used may not reflect achievable tissue levels. Single-receptor agonist comparison does not rule out involvement of other receptors. Acute treatment does not capture chronic exposure effects.

How to read the evidence

Mechanistically detailed in vitro study using primary human cells with appropriate controls, but lacks in vivo validation.

When this study was published

Published 2025.

The bigger picture

The finding that cannabinoids suppress inflammation through post-translational mechanisms rather than gene regulation is significant because it suggests faster-acting effects. It also explains why CB2 receptor agonists alone fail to replicate the anti-inflammatory profile of whole cannabinoids.

Questions still open

  • Which non-CB2 receptor mediates THC's superior efficacy over CBD in suppressing IL-1beta
  • Whether these anti-inflammatory effects translate to reduced disease activity in conditions like rheumatoid arthritis or HIV-associated inflammation

Common questions

What is IL-1beta and why does it matter?
IL-1beta is one of the most potent inflammatory signaling molecules in the body. It drives tissue damage in autoimmune diseases, contributes to fever, and plays a role in chronic inflammation associated with conditions like arthritis and cardiovascular disease.
Why could not a CB2-specific drug replicate the effect?
THC and CBD interact with multiple receptors and pathways beyond just CB1 and CB2. The fact that a CB2-selective agonist failed to suppress IL-1beta suggests the anti-inflammatory mechanism involves other targets, which researchers are still working to identify.

Read the original research

Δ9-Tetrahydrocannabinol and cannabidiol selectively suppress toll-like receptor (TLR) 7- and TLR8-mediated interleukin-1β production by human CD16+ monocytes by inhibiting its post-translational maturation.

The Journal of pharmacology and experimental therapeutics, 392(7), 103615

Citation

Sermet, Sera; Finn, Brianna M; Crawford, Robert B; Kaminski, Norbert E. (2025). Δ9-Tetrahydrocannabinol and cannabidiol selectively suppress toll-like receptor (TLR) 7- and TLR8-mediated interleukin-1β production by human CD16+ monocytes by inhibiting its post-translational maturation.. The Journal of pharmacology and experimental therapeutics, 392(7), 103615. https://doi.org/10.1016/j.jpet.2025.103615

Explore the wider topic